



Washington State Health Care Authority
Prescription Drug Program

1511 3rd Ave Suite 523 • Seattle, Washington 98101
206-521-2029 • www.hca.wa.gov/pdp

March 10, 2016

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority (Medicaid/Uniform Medical Plan) and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective April 1, 2016:

Hepatitis C – Direct-Acting Antivirals reviewed 10/21/2015		Agency Coverage		
Ingredient Name	Label Name of Preferred Product	L&I	Medicaid	UMP
ledipasvir/sofosbuvir	Harvoni [®] tablet	PA required	PA required	Yes
sofosbuvir	Sovaldi [®] tablet	PA required	PA required	Yes
The effect of this recommendation is no change to the PDL.				

Each agency will use the common PDL according to its benefit structure. You may view the current PDL at: <http://www.hca.wa.gov/pdp/Documents/washingtonpdl.pdf>.

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at leta.evaskus@hca.wa.gov.

Sincerely,

Ray Hanley
Prescription Drug Programs Director
Washington State Health Care Authority